NCT05468489
To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 27 versions: 26 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Phase changed: Phase 3 → Phase 2
- Eligibility criteria expanded, about 716 words
- Study sites: 67 to 65
- Secondary endpoints: 6 to 10
- Minor Trial status: Recruiting to Active, Not Recruiting
- Study sites: 99 to 67
- Primary completion date: Sep 30, 2025 to Feb 28, 2026
- Study completion date: Dec 31, 2025 to Dec 31, 2027
- Minor Site details revised at 6 of 99 sitesv25
- Minor Primary completion date: Apr 30, 2025 to Sep 30, 2025
- Study sites revised (99)
- Notable Primary completion date: Oct 31, 2024 to Apr 30, 2025
- Site details revised at 5 of 99 sites
Show 20 earlier versionsHide 20 earlier versions
- Minor Study sites: 87 to 99v22
- Minor Study sites revised (87)v21
- Minor Study sites: 84 to 87v20
- Notable Phase: Phase 2 to Phase 3v19
- Notable Phase: Phase 3 to Phase 2v18
- Minor Primary completion date: Jun 1, 2024 to Oct 31, 2024v17
- Minor Study sites: 83 to 84v16
- Minor Study sites: 79 to 83v15
- Minor Study sites: 69 to 79v14
- Minor Study sites: 64 to 69v13
- Minor Study sites: 57 to 64v12
- Notable Eligibility criteria expanded, about 108 wordsv11
- Minor Study sites: 38 to 57v10
- Minor Study sites: 15 to 38v9
- Minor Interventions: Atezolizumab + chemotherapy (carboplatin-etoposide) (Drug), HLX10 + chemotherapy (carboplatin-etoposide) (Drug) to Atezolizumab + chemotherapy (carboplatin-etoposide) (Drug), Serplulimab + chemotherapy (carboplatin-etoposide) (Drug)
- Secondary endpoints: details revised at 3 of 6 entries
- Study title revised
- Minor Study sites: 11 to 15v6
- Minor Study sites: 5 to 11
- Start date changed from estimate of Oct 12, 2022 to Nov 18, 2022
- Minor Study sites: 1 to 5v4
- Minor Start date: Oct 20, 2022 to Oct 12, 2022v3
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date: Sep 1, 2022 to Oct 20, 2022
- Study sites: 0 to 1
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
OS
Timeframe: A period from randomization through death regardless of causality (approximately up to 24 months).
Secondary (10)
Objective response rate (ORR)
Progression-free survival (PFS)
PFS2
Duration of response (DOR)
Adverse events
Show 5 moreShow less
Observed concentration of HLX10 in serum
Estimated PK exposure of HLX10 in serum from population pharmacokinetic analysis, expressed as mg·h/L
HLX10 anti-drug antibody (ADA)
Neutralizing antibody (NAb)
Quality of life assessment
Arms and interventions
Serplulimab + chemotherapyExperimental
Serplulimab + chemotherapy (carboplatin-etoposide)
Atezolizumab + chemotherapyActive comparator
Atezolizumab + chemotherapy (carboplatin-etoposide)
Drugs: Serplulimab + chemotherapy (carboplatin-etoposide), Atezolizumab + chemotherapy (carboplatin-etoposide)
Sites
65 sites in 1 country